Enlivex Pharmaceuticals Ltd., a cell immunotherapy company, is developing an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions which involve over-expression or hyper-expression of cytokines (Cytokine Release Syndrome) such as CAR-T (Chimeric Antigen Receptor) cancer treatment procedures, Graft-versus-Host disease (GvHD) resulting from bone-marrow transplantations, Sepsis and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis,  and other disorders. Our preventative and therapeutic approach is based on inducing immunotolerance, or the specific normal rebalancing of the immune system, through the utilization of our proprietary Allocetra platform.